Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection.

[1]  J. Mulenga,et al.  Donor and Recipient Envs from Heterosexual Human Immunodeficiency Virus Subtype C Transmission Pairs Require High Receptor Levels for Entry , 2010, Journal of Virology.

[2]  T. Zhou,et al.  P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment , 2009, Retrovirology.

[3]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[4]  S. Gnanakaran,et al.  Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.

[5]  R. Doms,et al.  Adaptive Mutations in a Human Immunodeficiency Virus Type 1 Envelope Protein with a Truncated V3 Loop Restore Function by Improving Interactions with CD4 , 2009, Journal of Virology.

[6]  Tongqing Zhou,et al.  Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.

[7]  Lynn Morris,et al.  Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.

[8]  S. Ratcliffe,et al.  Heterosexual Transmission of Human Immunodeficiency Virus Type 1 Subtype C: Macrophage Tropism, Alternative Coreceptor Use, and the Molecular Anatomy of CCR5 Utilization , 2009, Journal of Virology.

[9]  A. Perelson,et al.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.

[10]  C. Blish,et al.  Cross-Subtype Neutralization Sensitivity despite Monoclonal Antibody Resistance among Early Subtype A, C, and D Envelope Variants of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[11]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[12]  S Gnanakaran,et al.  Appreciating HIV type 1 diversity: subtype differences in Env. , 2009, AIDS research and human retroviruses.

[13]  D. Burton,et al.  Determinants Flanking the CD4 Binding Loop Modulate Macrophage Tropism of Human Immunodeficiency Virus Type 1 R5 Envelopes , 2009, Journal of Virology.

[14]  Cynthia A. Derdeyn,et al.  Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1 , 2009, PLoS pathogens.

[15]  J. Hoxie,et al.  Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma , 2008, Journal of Virology.

[16]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[17]  J. Mascola,et al.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. , 2008, Virology.

[18]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[19]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[20]  D. Burton,et al.  Edinburgh Research Explorer Variation in HIV-I R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors , 2022 .

[21]  C. Blish,et al.  Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41 , 2008, PLoS medicine.

[22]  L. Morris,et al.  The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[23]  R. Swanstrom,et al.  Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins , 2007, Journal of Virology.

[24]  L. Morris,et al.  N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization , 2007, Journal of Virology.

[25]  S Gnanakaran,et al.  Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120 , 2007, Journal of Virology.

[26]  S. Zolla-Pazner,et al.  Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. , 2007, AIDS research and human retroviruses.

[27]  S. Gnanakaran,et al.  Unique Mutational Patterns in the Envelope α2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.

[28]  Steven Wolinsky,et al.  Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. , 2007, Virology.

[29]  L. Ping,et al.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. , 2006, Virology.

[30]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[31]  S. Zolla-Pazner,et al.  Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C. , 2006, AIDS research and human retroviruses.

[32]  P. Simmonds,et al.  Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis , 2006, Journal of Virology.

[33]  S. Zolla-Pazner,et al.  Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity , 2006, Journal of Virology.

[34]  Xiping Wei,et al.  Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[35]  L. Morris,et al.  Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. , 2006, AIDS research and human retroviruses.

[36]  Peter B Gilbert,et al.  Covariability of selected amino acid positions for HIV type 1 subtypes C and B. , 2005, AIDS research and human retroviruses.

[37]  Bette Korber,et al.  Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.

[38]  C. Hoffmann,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides , 2005, Journal of Virology.

[39]  Peter D. Kwong,et al.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.

[40]  H. Kräusslich,et al.  T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. , 2005, Virology.

[41]  Don C. Wiley,et al.  Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.

[42]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[43]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[44]  B. Korber,et al.  The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. , 2004, Virology.

[45]  Bette T. Korber,et al.  Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.

[46]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[47]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[48]  Emmanuel G. Cormier,et al.  The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor , 2002, Journal of Virology.

[49]  Feng Gao,et al.  Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.

[50]  D. Montefiori,et al.  Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa , 2002, Journal of Virology.

[51]  Susan Zolla-Pazner,et al.  A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.

[52]  Cynthia A. Derdeyn,et al.  Molecular Epidemiology of Human Immunodeficiency Virus Type 1 Transmission in a Heterosexual Cohort of Discordant Couples in Zambia , 2002, Journal of Virology.

[53]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[54]  T. Ndung’u,et al.  Construction and Analysis of an Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone , 2001, Journal of Virology.

[55]  L. Morris,et al.  CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. , 2001, AIDS research and human retroviruses.

[56]  J. Sodroski,et al.  The Level of CD4 Expression Limits Infection of Primary Rhesus Monkey Macrophages by a T-Tropic Simian Immunodeficiency Virus and Macrophagetropic Human Immunodeficiency Viruses , 2000, Journal of Virology.

[57]  W A Hendrickson,et al.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.

[58]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[59]  B. Chesebro,et al.  Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[60]  C. Luo,et al.  Rapid HIV testing and counseling for voluntary testing centers in Africa. , 1997, AIDS.

[61]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[62]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[63]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[64]  R. F. Smith,et al.  Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1 , 1994, Journal of virology.

[65]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[66]  B. Chesebro,et al.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.

[67]  M. Martin,et al.  Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1 , 1994, Journal of virology.

[68]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[69]  J. Moore,et al.  Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. , 1993, AIDS research and human retroviruses.

[70]  J. Sodroski,et al.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.

[71]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[72]  B. Cullen,et al.  Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. , 1992, Science.

[73]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[74]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[75]  D. Ho,et al.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[76]  E. Freed,et al.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain , 1991, Journal of virology.

[77]  H. Friedman,et al.  Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor , 1990, Journal of virology.

[78]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[79]  R. Garlick,et al.  Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. , 1990, AIDS research and human retroviruses.

[80]  J. Goudsmit,et al.  ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY , 1989, The Lancet.